| Bioactivity | Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with drug-likeness properties, possessing anticancer activity against several cancer cell lines (IC50<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9[1]. |
| Target | IC50: 0.64 ± 0.02 μM in Leukemia RPMI-8226, 0.96 ± 0.04 μM in Leukemia SR, 0.84 ± 0.07 μM in Leukemia K-562, 0.69 ± 0.01 μM in Melanoma M14, 0.24 ± 0.01 μM in Breast MCF7, 0.26 ± 0.01 μM in Colon HCT116, 2.95 ± 0.14 μM in Prostate PC3 |
| Name | Anticancer agent 56 |
| CAS | 2241915-59-1 |
| Formula | C20H18ClN3O3 |
| Molar Mass | 383.83 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ashour HF, et al. 1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. Eur J Med Chem. 2020;189:112062. |
Anticancer agent 56
CAS: 2241915-59-1 F: C20H18ClN3O3 W: 383.83
Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with drug-likeness properties, possessing anticancer act
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.